ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
38 announcements
Wanbury Ltd reported revenue from operations of ₹182.9 Cr (+14.2% YoY) and net profit of ₹11.9 Cr (-21.7% YoY) for Q2 FY27.
Wanbury's Tanuku plant received an Australian TGA GMP certificate covering six APIs. This strengthens the company's global pharmaceutical manufacturing credentials.
Wanbury Limited has scheduled its Board Meeting for 4 Nov 2026 to consider unaudited half-year results. No financial figures or material decisions are disclosed in this advance intimation.
Wanbury Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI listing regulations.
Wanbury Limited received nine "No DMF Deficiency" letters from the USFDA for Metformin HCl. The company also expanded its business in Saudi Arabia and Mexico with an annual revenue potential of Rs 25 Crore.
Wanbury Skin Health launched its berrysoft baby product range across multiple Indian states. This marks the company's strategic entry into the paediatric dermatology segment.
Wanbury filed new Drug Master Files in South Africa, Philippines and Singapore for its APIs. It also added KSM vendors and received EDQM/TGA compliance clearances.
Wanbury Limited announced the appointment of ABK & Associates as Cost Auditor and the re-appointment of Mohan Kumar Rayana as Executive Director.
Wanbury Limited held its 38th Annual General Meeting on September 24, 2026. Shareholders approved financial statements, director re-appointments, and cost auditor remuneration ratification.
Wanbury Limited has issued a notice for its Annual General Meeting scheduled on September 24, 2026, to transact various business resolutions.
Wanbury Limited has scheduled its 38th Annual General Meeting for September 24, 2026. The meeting will address ordinary business, director re-appointments, and cost auditor remuneration.
Wanbury Limited received EDQM approval for Rivaroxaban API. The company also obtained USFDA DMF clearances for Paroxetine HCI and Metformin HCI.
Wanbury reported Q1 FY27 financial results in a press release. The company also completed a Rs. 205 crore debt refinancing, improving its borrowing profile.
Wanbury Limited allotted equity shares under its Employee Stock Option Plan (ESOP). This issuance increases the company's total paid-up share capital.
Wanbury Limited has announced the re-appointment of Mr. Mohan Kumar Rayana as an Executive Director, effective August 21, 2026, for a 60-month term.
Wanbury Ltd reported revenue from operations of ₹165.6 Cr (+1.5% YoY) and net profit of ₹3.2 Cr (-76.3% YoY) for Q1 FY27.
Wanbury Limited has scheduled a board meeting for August 11, 2026, to consider its unaudited standalone financial results for the quarter ended June 2026.
Wanbury Limited received a 'No DMF deficiency' letter from the USFDA for multiple ANDAs. This clearance facilitates expansion into the South Korean API market.
Wanbury Limited announced that the USFDA completed a cGMP inspection at its Tanuku facility, resulting in a Form 483 with six observations.
Wanbury Limited clarified that recent stock price increases are entirely market-driven. The company confirmed no undisclosed material information exists that could impact trading activity.
Wanbury Limited approved the early redemption of Rs. 180 Crore worth of 12.5% Non-Convertible Debentures. This full redemption will be completed before the February 2030 maturity date.
Wanbury Ltd disclosed Catalyst Trusteeship Ltd, as debenture trustee, released a pledge on 85,20,330 shares on July 6, 2026. The release lowers equity encumbrance.
Wanbury achieved a major turnaround in FY26, reporting highest-ever operational EBITDA of ₹108 Cr and 117% PAT growth.
Wanbury Limited appointed Ernst & Young LLP as Internal Auditors. ABK & Associates were also appointed as Cost Auditors for a 12-month term.
Wanbury approved incorporating subsidiary Wanbury Skin Health Limited with an outlay of ₹0.041 Crore. The company also appointed Ernst & Young LLP as internal auditor.
Wanbury announced release of pledge on 1,42,03,818 shares, reducing pledged portion to 5.49% with SBM. The company’s borrowing cost will drop below 10% p.a. from 1 July 2026.
Wanbury Limited's Tanuku site successfully completed Australia's TGA inspection. This regulatory milestone enables the company to export three additional APIs to the Australian market.
Wanbury Limited launched new APIs globally through regulatory submissions in Singapore, Malaysia, and Korea. The Patalganga facility also received zero observations from Korea's MFDS.
Wanbury Limited reported ₹650.3 Crore revenue for FY26, with PAT surging 117% to ₹66.1 Crore. Strong growth was driven by new API launches and improved margins.
Wanbury Ltd reported revenue from operations of ₹164.6 Cr (-4.3% YoY) and net profit of ₹21.7 Cr (+6.9% YoY) for Q4 FY26.